TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Geriatrician Nathaniel Chin says persistent subjective cognitive decline can warrant evaluation even when cognitive test scores remain normal. He stresses that it is not a diagnosis of Alzheimer’s and that sleep, mood, medications and other health factors can also affect thinking. The article describes baseline and repeat testing, and biomarker tests for selected patients, as possible parts of assessment.
Geriatrician Nathaniel Chin says persistent concerns about memory or thinking can merit a fuller clinical evaluation even when comprehensive testing shows no objective impairment, describing this period as a possible early window for Alzheimer’s prevention and treatment. In an essay published October 27, he emphasizes that subjective cognitive decline is a description of a person’s experience, not proof of Alzheimer’s disease.
Chin, a memory-care physician at UW Health and an associate professor at the University of Wisconsin–Madison, describes patients who report forgetting conversations, using more notes or finding that thinking takes greater effort while still scoring within the expected range. He argues that a normal result should not, by itself, end the discussion. People can experience a meaningful change from their own prior ability without falling below a population-based cutoff.
He distinguishes a short screening test from a comprehensive cognitive evaluation. Screenings commonly take five to 15 minutes and sample a limited range of abilities. A fuller assessment typically takes an hour or more and examines memory, language, attention and executive function. Chin says careful testing helps establish whether objective impairment is present and gives clinicians a baseline to compare against later results.
He recommends considering other possible contributors, including sleep problems, medication effects, depression or anxiety, medical illness, vascular disease, hearing loss, stress and normal aging. For some patients, he says, assessment can also include blood biomarkers, cerebrospinal fluid testing or amyloid PET to investigate whether Alzheimer’s-related biological changes are present. His article frames these as options for selected patients, not as a routine or definitive test for everyone with memory concerns.
Why Normal Scores May Not End Follow-Up
The issue matters because a single score may not capture change from an individual’s earlier abilities. Chin uses the example of a retired engineer whose skills were once well above average: a decline could bring that person into the average range without producing a score classified as impaired. A personal baseline and repeat assessments can help clinicians look for consistent change over time, rather than relying only on whether a score crosses a threshold.
The approach also offers a more measured alternative to either dismissing concerns or assuming they signal dementia. Persistent symptoms may justify discussion, evaluation and follow-up, while checking for other explanations. Chin’s argument is that taking concerns seriously can support earlier clinical attention; it does not establish that early intervention will prevent Alzheimer’s or that every person reporting decline would benefit from biomarker testing.
Products Worth Considering
Blueair Blue Pure 511i Max Air Purifier for Home and Bedroom
Philips Sonicare DiamondClean 9500 Electric Toothbrush with 3 Brush Heads – Black
Therabody SleepMask Blackout Eye Mask with Vibration
As an affiliate, we earn on qualifying purchases.
How Clinicians Assess Subjective Decline
Subjective cognitive decline (SCD) refers to a person’s persistent sense that their cognitive abilities have worsened compared with their previous level, despite testing that does not show objective impairment. The distinction depends on adequate evaluation: a brief screening alone may not be enough to establish that impairment is absent.
Chin describes the “SCD-plus” features developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. These include memory-focused concerns, onset within the past five years, onset at age 60 or older, worry, persistence, seeking medical help and confirmation by someone who knows the person well. No single feature proves Alzheimer’s; several together may warrant closer attention.
For example, Chin contrasts longstanding, intermittent word-finding concerns linked to stress or poor sleep with a newer, persistent memory change noticed by both a person and their spouse. Both people could have normal scores, he writes, but the pattern and supporting observations would call for different clinical consideration.
What Symptoms Cannot Establish Alone
The article does not report a new clinical trial, new diagnostic guideline or measured outcome showing that this approach prevents Alzheimer’s disease. It is a physician’s perspective on assessment and follow-up, not evidence that subjective decline reliably predicts an individual’s future diagnosis. SCD has multiple possible causes, and the features described as SCD-plus raise concern without confirming Alzheimer’s.
Chin’s discussion does not specify which patients should receive blood, spinal-fluid or PET testing, how clinicians should choose among them, or how results should change care in each case. Nor does it provide estimates of the likelihood that a person with SCD will develop Alzheimer’s. Those questions require individualized clinical judgment and evidence beyond the essay.
Baseline Testing and Follow-Up
Chin says that for persistent concerns, particularly when several SCD-plus features are present, clinicians should consider a thorough cognitive baseline, review possible contributors and gather observations from someone close to the person when possible. Repeat testing over time can then help show whether abilities remain stable or decline consistently. The article gives no fixed follow-up interval.
For selected patients, a clinician may discuss Alzheimer’s biomarkers as part of evaluating the cause of symptoms. The next steps depend on the person’s history, examination and available testing; the essay does not announce a new program or a specific change in clinical policy.
Key Questions
Does subjective cognitive decline mean someone has Alzheimer’s?
No. SCD describes a perceived change in thinking despite testing that does not show objective impairment. Chin notes that many other factors can contribute, and the symptom alone does not identify its cause.
Why might a person have normal test scores after noticing a change?
Testing often compares a person with others of similar age, not with their own earlier abilities. Someone may decline from a high previous level and still score within the expected range. A baseline and repeat testing can help clarify a pattern over time.
Which features may make subjective decline more concerning?
Chin describes SCD-plus features such as memory-focused, persistent or recent concerns; worry; seeking medical help; onset at age 60 or older; and confirmation by someone who knows the person well. These features do not diagnose Alzheimer’s, but several together may support closer evaluation.
Can biomarkers detect Alzheimer’s before cognitive impairment?
Chin says blood tests, cerebrospinal fluid testing and amyloid PET can help selected patients assess whether Alzheimer’s-related biological changes are present. His article does not set out who should receive these tests or how every result should guide care, so testing decisions are a matter for a qualified clinician.
Source: beingpatient.com
